MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Retained Earnings 2011-2026 | ZOM
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -300 M | -218 M | -171 M | -136 M | -119 M | - | -52.1 M | -32.3 M | -15.6 M | -158 K | -112 K | -78.7 K | -1.34 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.34 K | -300 M | -87.1 M |
Quarterly Retained Earnings Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -295 M | -289 M | -282 M | -218 M | -211 M | -204 M | - | -171 M | -149 M | -148 M | -143 M | -136 M | -134 M | -129 M | -123 M | -119 M | -116 M | -110 M | -105 M | -69 M | -69 M | -69 M | -69 M | -52.1 M | -52.1 M | -52.1 M | -52.1 M | -32.3 M | -32.3 M | -32.3 M | -32.3 M | -15.6 M | -15.6 M | -15.6 M | -15.6 M | -7.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.56 M | -295 M | -108 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.53 | 2.17 % | $ 86.3 M |  Canada |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.55 | 0.39 % | $ 1.33 B | Canada |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.06 | 3.92 % | $ 114 M | Canada |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
-703 M | $ 12.09 | 2.72 % | $ 77.4 M | USA |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
-661 M | $ 4.77 | -5.36 % | $ 308 M | USA |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.01 | -1.63 % | $ 42.3 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
-157 M | $ 35.11 | 0.57 % | $ 1.29 B | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.56 | -0.97 % | $ 337 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 8.13 | -2.4 % | $ 416 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.44 | 1.56 % | $ 402 M | Canada |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 21.79 | -3.99 % | $ 1.01 B | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 0.61 | -2.26 % | $ 10.7 M |  China |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.45 | 0.35 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-295 M | $ 2.44 | 2.74 % | $ 329 M | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.3 | 5.99 % | $ 24 M | USA |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Viatris
VTRS
|
5.18 B | $ 13.84 | 2.43 % | $ 16.6 B | USA |
 |
Perrigo Company plc
PRGO
|
-3.68 B | $ 10.44 | 7.36 % | $ 1.45 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 2.45 | 1.66 % | $ 3.04 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 6.39 | 3.4 % | $ 192 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 1.05 | 9.39 % | $ 24.5 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
-385 M | $ 0.92 | 2.01 % | $ 45.9 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 7.8 | 4.28 % | $ 318 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 6.96 | 0.87 % | $ 4.3 B | Canada |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 0.75 | 4.19 % | $ 3.23 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |